This study aimed to explore the use of serum free testosterone concentrations in transmasculine patients as a more reliable indicator of gender-affirming testosterone therapy than total testosterone concentration. Total testosterone values, recommended by current guidelines, may be impacted by obesity. In addition, this study aimed to characterize the impact of testosterone concentrations on hematocrit and the risk of polycythemia.
Methods:
A retrospective study was conducted of transmasculine patients seen at Boston Children’s Hospital Gender Multispecialty Service from 2007 to 2020. Sixty-eight birth-assigned female adolescents who were receiving gender-affirming testosterone therapy and had total and free testosterone concentrations were included. The aims were to determine the fidelity of total and free testosterone concentrations with body mass index (BMI) and to characterize the association of testosterone concentrations with erythrocytosis.
Results:
Of 68 subjects, 23% were overweight and 40% had obesity. Compared with the group with a healthy BMI, patients with obesity had significantly lower total testosterone concentrations. Free testosterone concentrations did not vary based on BMI category. BMI z-score was inversely correlated with total testosterone, sex hormone-binding globulin, and albumin concentrations but not with free testosterone concentrations. Four percent of subjects developed erythrocytosis (e.g., hematocrit >50%). Neither BMI nor testosterone concentrations were correlated with hematocrit.
Conclusions:
Free testosterone concentrations are an adjunctive tool in the monitoring of gender-affirming testosterone therapy. In addition, the development of erythrocytosis is independent of serum testosterone concentration and warrants further study to understand factors that may predispose patients to developing secondary polycythemia.
Get full access to this article
View all access options for this article.
References
1.
SkordisN, ButlerG, de VriesMC, et al.ESPE and PES international survey of centers and clinicians delivering specialist care for children and adolescents with gender dysphoria. Horm Res Paediatr, 2018; 90(5):326–331; doi: 10.1159/000496115
2.
ChenM, FuquaJ, EugsterEA. Characteristics of referrals for gender dysphoria over a 13-year period. J Adolesc Health, 2016; 58(3):369–371; doi: 10.1016/j.jadohealth.2015.11.010
3.
HandlerT, HojillaJC, VargheseR, et al.Trends in referrals to a pediatric transgender clinic. Pediatrics, 2019; 144(5):e20191368; doi: 10.1542/peds.2019-1368
4.
ArnoldussenM, SteensmaTD, PopmaA, et al.Re-evaluation of the Dutch approach: Are recently referred transgender youth different compared to earlier referrals? Eur Child Adolesc Psychiatry, 2020; 29(6):803–811; doi: 10.1007/s00787-019-01394-6
5.
BauerGR, PacaudD, CouchR, et al.Trans Youth CAN! Research Team. Transgender youth referred to clinics for gender-affirming medical care in Canada. Pediatrics, 2021; 148(5):e2020047266; doi: 10.1542/peds.2020-047266
6.
KaltialaR, BergmanH, CarmichaelP, et al.Time trends in referrals to child and adolescent gender identity services: A study in four Nordic countries and in the UK. Nord J Psychiatry, 2020; 74(1):40–44; doi: 10.1080/08039488.2019.1667429
7.
ZhangQ, RechlerW, BradlynA, et al.Changes in size and demographic composition of transgender and gender non-binary population receiving care at integrated health systems. Endocr Pract, 2021; 27(5):390–395; doi: 10.1016/j.eprac.2020.11.016
8.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: An endocrine society* clinical practice guideline. J Clin Endocrinol Metab, 2017; 102(11):3869–3903; doi: 10.1210/jc.2017-01658
9.
ColemanE, RadixAE, BoumanWP, et al.Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health, 2022; 23(Suppl 1):S1–S259; doi: 10.1080/26895269.2022.2100644
10.
OlsonJ, SchragerSM, ClarkLF, et al.Subcutaneous testosterone: An effective delivery mechanism for masculinizing young transgender men. LGBT Health, 2014; 1(3):165–167; doi: 10.1089/lgbt.2014.0018
11.
LaurenzanoSE, NewfieldRS, LeeE, et al.Subcutaneous testosterone is effective and safe as gender-affirming hormone therapy in transmasculine and gender-diverse adolescents and young adults: A single center’s 8-year experience. Transgend Health, 2021; 6(6):343–352; doi: 10.1089/trgh.2020.0103
12.
FornanderMJ, RobertsT, EganAM, et al.Weight status, medication use, and recreational activities of treatment-naïve transgender youth. Child Obes, 2022; 18(4):228–236; doi: 10.1089/chi.2021.0155
13.
ValentineA, NokoffN, BonnyA, et al.Cardiometabolic parameters among transgender adolescent males on testosterone therapy and body mass index-matched cisgender females. Transgend Health, 2021; 6(6):369–373; doi: 10.1089/trgh.2020.0052
14.
JenssenBP, KellyMK, PowellM, et al.Covid-19 and changes in child obesity. Pediatrics, 2021; 147(5):e2021050123; doi: 10.1542/peds.2021-050123
15.
YangQ, LiZ, LiW, et al.Association of total testosterone, free testosterone, bioavailable testosterone, sex hormone–binding globulin, and hypertension. Medicine (Baltimore), 2019; 98(20):e15628; doi: 10.1097/MD.0000000000015628
16.
BhasinS, BritoJP, CunninghamGR, et al.Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2018; 103(5):1715–1744; doi: 10.1210/jc.2018-00229
17.
KuczmarskiRJ, OgdenCL, GuoSS, et al.2000 CDC growth charts for the United States: Methods and development. Vital Health Stat, 2002; 11(246):1–190.
18.
BarlowSE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics, 2007; 120(Suppl 4):S164–S192; doi: 10.1542/peds.2007-2329C
19.
StyneDM, ArslanianSA, ConnorEL, et al.Pediatric obesity-assessment, treatment, and prevention: An endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2017; 102(3):709–757; doi: 10.1210/jc.2016-2573
20.
VermeulenA, VerdonckL, KaufmanJM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab, 1999; 84(10):3666–3672; doi: 10.1210/jcem.84.10.6079
21.
ChewD, TollitMA, PoulakisZ, et al.Youths with a non-binary gender identity: A review of their sociodemographic and clinical profile. Lancet Child Adolesc Health, 2020; 4(4):322–330; doi: 10.1016/S2352-4642(19)30403-1
22.
KiddKM, SequeiraGM, DharCP, et al.Gendered body mass index percentile charts and transgender youth: Making the case to change charts. Transgend Health, 2019; 4(1):297–299; doi: 10.1089/trgh.2019.0016
23.
Olson-KennedyJ, OkontaV, ClarkLF, et al.Physiologic response to gender-affirming hormones among transgender youth. J Adolesc Health, 2018; 62(4):397–401; doi: 10.1016/j.jadohealth.2017.08.005
24.
MillingtonK, FinlaysonC, Olson-KennedyJ, et al.Association of high-density lipoprotein cholesterol with sex steroid treatment in transgender and gender-diverse youth. JAMA Pediatr, 2021; 175(5):520–521; doi: 10.1001/jamapediatrics.2020.5620
25.
SprattDI, StewartII, SavageC, et al.Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: Demonstration in female-to-male transgender patients. J Clin Endocrinol Metab, 2017; 102(7):2349–2355; doi: 10.1210/jc.2017-00359
26.
KupelianV, PageST, AraujoAB, et al.Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab, 2006; 91(3):843–850; doi: 10.1210/jc.2005-1326
27.
BuiHN, SlussPM, HayesFJ, et al.Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clinica Chimica Acta, 2015; 450:227–232; doi: 10.1016/j.cca.2015.08.019
28.
MosliRH, MosliHH. Obesity and morbid obesity associated with higher odds of hypoalbuminemia in adults without liver disease or renal failure. Diabetes Metab Syndr Obes, 2017; 10:467–472; doi: 10.2147/DMSO.S149832
29.
BachmanE, TravisonTG, BasariaS, et al.Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci, 2014; 69(6):725–735; doi: 10.1093/gerona/glt154
30.
HaiderMZ, AnwerF. Secondary Polycythemia. StatPearls Publishing: Treasure Island (FL); 2022.
31.
MullinsES, GeerR, MetcalfM, et al.Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy. Pediatrics, 2021; 147(4):e2020023549; doi: 10.1542/peds.2020-023549
32.
MadsenMC, van DijkD, WiepjesCM, et al.Erythrocytosis in a large cohort of trans men using testosterone: A long-term follow-up study on prevalence, determinants, and exposure years. J Clin Endocrinol Metab, 2021; 106(6):1710–1717; doi: 10.1210/clinem/dgab089
33.
NolanBJ, LeemaqzSY, OoiO, et al.Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. Intern Med J, 2021; 51(6):873–878; doi: 10.1111/imj.14839
34.
McFarlandJ, CraigW, ClarkeNJ, et al.Serum testosterone concentrations remain stable between injections in patients receiving subcutaneous testosterone. J Endocr Soc, 2017; 1(8):1095–1103; doi: 10.1210/js.2017-00148
35.
KeyTJ, AllenNE, VerkasaloPK, et al.Energy balance and cancer: The role of sex hormones. Proc Nutr Soc, 2001; 60(1):81–89; doi: 10.1079/PNS200068
36.
GrimstadFW, KnollMM, JacobsonJD. Oxandrolone use in trans-masculine youth appears to increase adult height: Preliminary evidence. LGBT Health, 2021; 8(4):300–306; doi: 10.1089/lgbt.2020.0355
37.
MillingtonK, SchulmeisterC, FinlaysonC, et al.Physiological and metabolic characteristics of a cohort of transgender and gender-diverse youth in the United States. J Adolesc Health, 2020; 67(3):376–383; doi: 10.1016/j.jadohealth.2020.03.028
